Literature DB >> 11952036

Infantile spasms and Lennox-Gastaut syndrome.

Edwin Trevathan1.   

Abstract

Infantile spasms and Lennox-Gastaut syndrome are rare but are important to child neurologists because of the intractable nature of the seizures and the serious neurologic comorbidities. New antiepileptic drugs offer more alternatives for treating both infantile spasms and Lennox-Gastaut syndrome. Selected children with infantile spasms are candidates for epilepsy surgery. Vagus nerve stimulation, corpus callosotomy, and the ketogenic diet are all options for selected children with Lennox-Gastaut syndrome. The epidemiology, clinical manifestations of the seizures, electroencephalographic characteristics, prognosis, and treatment options are reviewed for infantile spasms and Lennox-Gastaut syndrome. Additional therapies are needed for both infantile spasms and Lennox-Gastaut syndrome as many children fail to achieve adequate seizure control in spite of newer treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952036     DOI: 10.1177/08830738020170021201

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

Review 1.  Neuroprotective and disease-modifying effects of the ketogenic diet.

Authors:  Maciej Gasior; Michael A Rogawski; Adam L Hartman
Journal:  Behav Pharmacol       Date:  2006-09       Impact factor: 2.293

2.  Corpus callosotomy in children.

Authors:  Tai-Tong Wong; Shang-Yeong Kwan; Kai-Ping Chang; Wu Hsiu-Mei; Tsui-Fen Yang; Ying-Sheue Chen; Lee Yi-Yen
Journal:  Childs Nerv Syst       Date:  2006-07-08       Impact factor: 1.475

Review 3.  Neurologic complications of Down syndrome: a systematic review.

Authors:  Jonathan D Santoro; Dania Pagarkar; Duong T Chu; Mattia Rosso; Kelli C Paulsen; Pat Levitt; Michael S Rafii
Journal:  J Neurol       Date:  2020-09-12       Impact factor: 6.682

4.  Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function.

Authors:  Vaishali S Janve; Ciria C Hernandez; Kelienne M Verdier; Ningning Hu; Robert L Macdonald
Journal:  Ann Neurol       Date:  2016-05       Impact factor: 10.422

5.  Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

Authors:  Jennifer T Leahy; Catherine J Chu-Shore; Janet L Fisher
Journal:  Neuropsychiatr Dis Treat       Date:  2011-11-11       Impact factor: 2.570

6.  Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide.

Authors:  Russell P Saneto; Gail D Anderson
Journal:  Ther Clin Risk Manag       Date:  2009-05-04       Impact factor: 2.423

7.  Lennox gastaut syndrome, review of the literature and a case report.

Authors:  Tareq Abu Saleh; Lawrence Stephen
Journal:  Head Face Med       Date:  2008-06-09       Impact factor: 2.151

8.  Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.

Authors:  Joan A Conry; Yu-Tze Ng; Lydia Kernitsky; Wendy G Mitchell; Rima Veidemanis; Rebecca Drummond; Jouko Isojarvi; Deborah Lee; Juliann M Paolicchi
Journal:  Epilepsia       Date:  2014-03-01       Impact factor: 5.864

9.  GABAA receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice.

Authors:  Shimian Qu; Mackenzie Catron; Chengwen Zhou; Vaishali Janve; Wangzhen Shen; Rachel K Howe; Robert L Macdonald
Journal:  Brain Commun       Date:  2020-03-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.